Transaction Date | Recipient | Shares | Type | Price | Value |
---|---|---|---|---|---|
31st December 2020 | John W. Higuchi | 1,700 | Open or private sale | $1.35 | $2,286.50 |
31st December 2020 | John W. Higuchi | 5,000 | Open or private sale | $1.35 | $6,767.00 |
16th December 2020 | Jeffrey Arvin Fink | 5,625 | Exercise of derivative | $0.00 | |
16th December 2020 | Mahesh V. Patel | 15,000 | Open or private sale | $1.35 | $20,250.00 |
16th December 2020 | Mahesh V. Patel | 45,000 | Exercise of derivative | $0.00 | |
16th December 2020 | John W. Higuchi | 3,750 | Exercise of derivative | $0.00 | |
16th December 2020 | Morgan R Brown | 8,437 | Open or private sale | $1.35 | $11,389.95 |
16th December 2020 | Morgan R Brown | 28,125 | Exercise of derivative | $0.00 | |
16th December 2020 | Richard Dana Ono | 5,250 | Exercise of derivative | $0.00 | |
16th December 2020 | Stephen A Hill | 7,500 | Exercise of derivative | $0.00 |
Based on disclosure changes, sentiment, insider trading and news impact we give a rating of 10/10.
Lipocine, Inc. focuses on the oral testosterone replacement therapy and preterm birth prevention. The company was founded in 2011 and is headquartered in Salt Lake City, UT.